← Back to Search

Ixazomib Citrate for Multiple Myeloma

Q: What medical condition does Ixazomib Citrate target?

<p>Ixazomib Citrate is used to treat <a href="https://www.withpower.com/clinical-trials/multiple-myeloma">multiple myeloma</a>, as well as other blood cancers such as relapsed and/or refractory <a href="https://www.withpower.com/clinical-trials/lymphoma">lymphoma</a> and <a href="https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia">chronic lymphocytic leukemia</a>.</p>

Phase 2

Waitlist Available

Led By Krina Patel

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 30 days after completion of study treatment

Awards & highlights

Study Summary

This trial is studying ixazomib citrate and lenalidomide to treat newly diagnosed multiple myeloma.

Eligible Conditions

Multiple Myeloma
Bone Marrow Transplant Recipient

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time from autologous stem cell transplant (asct) to time of clinical progression or death or the time of last contact, assessed up to 30 days after completion of study treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time from autologous stem cell transplant (asct) to time of clinical progression or death or the time of last contact, assessed up to 30 days after completion of study treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and time from autologous stem cell transplant (asct) to time of clinical progression or death or the time of last contact, assessed up to 30 days after completion of study treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events

Progression-free survival

Secondary outcome measures

Best response rate (stringent complete response [sCR]/near complete response [nCR]/very good partial response [VGPR]/partial response [PR])

Malignant Neoplasms

M. D. Anderson Symptom Inventory (MDASI)-myeloma symptom evaluation

+2 more

Side effects data

From 2021 Phase 2 trial • 8 Patients • NCT03202628

100%

Fatigue

100%

Neutrophil count decreased

100%

White blood cell decreased

88%

Platelet count decreased

75%

Diarrhea

75%

Lymphocyte count decreased

63%

Constipation

63%

Peripheral sensory neuropathy

50%

Nausea

50%

Creatinine increased

25%

Hyperglycemia

13%

Urinary tract infection

13%

Wrist fracture

13%

Cardiac disorders - Other, specify

13%

Vomiting

13%

Anorexia

13%

Insomnia

13%

Hypoxia

13%

Resp, thoracic, mediastinal - Oth spec

13%

Hypoglycemia

13%

Tremor

13%

Anemia

13%

Blood and lymph sys disorders - Oth Spec

13%

Febrile neutropenia

13%

Fever

13%

Alkaline phosphatase increased

13%

Pneumonitis

13%

Rash maculo-papular

13%

Thromboembolic event

100%

80%

60%

40%

20%

Study treatment Arm

Treatment (Ixazomib, Pomalidomide, Dexamethasone, ASCT)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (ixazomib citrate, lenalidomide)Experimental Treatment3 Interventions

Beginning 60-180 days post-transplant, patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ixazomib Citrate

2012

Completed Phase 2

~200

Lenalidomide

2005

Completed Phase 3

~1480

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,971 Previous Clinical Trials

1,787,133 Total Patients Enrolled

76 Trials studying Multiple Myeloma

5,734 Patients Enrolled for Multiple Myeloma

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,406 Total Patients Enrolled

579 Trials studying Multiple Myeloma

189,048 Patients Enrolled for Multiple Myeloma

Krina PatelPrincipal InvestigatorM.D. Anderson Cancer Center

1 Previous Clinical Trials

30 Total Patients Enrolled

1 Trials studying Multiple Myeloma

30 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When was Ixazomib Citrate approved by the FDA?

"While there is data supporting Ixazomib Citrate's safety, it received a score of 2 because efficacy has not been clinically proven."

Answered by AI

What medical condition does Ixazomib Citrate target?

"Ixazomib Citrate is used to treat multiple myeloma, as well as other blood cancers such as relapsed and/or refractory lymphoma and chronic lymphocytic leukemia."

Answered by AI

What are the aims of this clinical research?

"The goal of this trial is to assess the incidence of adverse events over a period of time from autologous stem cell transplant (ASCT) to clinical progression or death, or last contact 30 days after completion of study treatment. Secondary outcomes include treatment-related unmanageable toxicities, overall survival, and best response rate."

Answered by AI

Are there any unfilled vacancies for people who want to participate in this clinical trial?

"As of September 22nd, 2022, this study is no longer actively enrolling patients. The trial was originally posted on December 3rd, 2012. If you are seeking other studies, 845 trials for neoplasms and plasma cell research are ongoing as well as 323 clinical trials involving Ixazomib Citrate."

Answered by AI

How many individuals can join this research project?

"Currently, this clinical trial is not enrolling patients. According to the posting on clinicaltrials.gov, which was last updated on September 22nd, 2022, the study was originally posted December 3rd, 2012. If you are looking for other trials, 845 studies related to neoplasms and plasma cell research are actively recruiting participants; additionally, 323 trials involving Ixazomib Citrate are also searching for patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

2012. "Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01718743.